Global Neurodiagnostics Market
Global Neurodiagnostics Market

Neurodiagnostics Comprehensive Study by Disease (Alzheimer’s Disease, Migraine, Multiple Sclerosis), Technology (Neuroimaging (Computed Tomography, Magnetic Resonance Imaging, Nuclear Medicine Imaging, Near-Infrared Spectroscopic Imaging, Electroencephalography, Magnetoencephalographya and Voxel-Based Morphometry), In Vitro Diagnosis, Neuroinformatics), End-user (Clinic, Hospitals, Diagnostic Laboratories) Players and Region - Global Market Outlook to 2025

Neurodiagnostics Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Mar 2020 Edition 265 Pages 212 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Scope of the Study

Neurodiagnostics is a field of science devoted to recording and studying the electrical activity of the brain and nervous system. It is used to detect neurological disorders involving stroke, migraine, epilepsy, Parkinson's disease, and ischemic stroke.

The market study is being classified and major geographies with country level break-up.

GE Healthcare (United States), Siemens Healthineers (Germany), Philips Healthcare (Netherlands), Hitachi, Ltd. (Japan), Canon, Inc. (Japan), Lifelines Neuro Company, LLC (United States), Natus Medical Incorporated (United States), Hoffman-La Roche AG (Switzerland), FUJIFILM Holdings Corporation (Japan) and Mitsar Co., Ltd. (Russia) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Advanced Brain Monitoring (United States), Thermo Fisher Scientific, Inc. (United States), Bio-Rad Laboratories (United States) and QIAGEN N.V. (Netherlands).

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Neurodiagnostics market throughout the predicted period.

Segment Analysis
AdvanceMarketAnalytics has segmented the market of Global Neurodiagnostics market by Type, Application and Region.

On the basis of geography, the market of Neurodiagnostics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Rise in the Prevalence of Neurological Diseases and Disorders
  • Technological Advancements in the Field of Medical Science

Market Trend
  • Growing Patient Emphasis on Effective and Early Disease Diagnosis

Restraints
  • High Cost of Neurodiagnostics
  • Limitations Associated with Neurodiagnostics

Opportunities
  • Development of Healthcare Infrastructure in Emerging Economies
  • Growing Geriatric Population Worldwide

Challenges
  • Lack of Skilled Workforce


Market Leaders and their expansionary development strategies
In August 2019, Royal Philips, a global leader in health technology, has announced that it has completed the previously announced acquisition of Carestream Health Inc.’s Healthcare Information Systems (HCIS) business in 26 of the 38 countries in which it operates. Carestream HCIS’s cloud-enabled enterprise imaging platform will expand Philips’ current enterprise diagnostic informatics solutions, including productivity enhancement, imaging data management, and advanced visualization and analysis.



Key Target Audience
Neurodiagnostics Providers, Research Professionals, Emerging Companies, Distributors, Government Body & Associations and End users

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Disease
  • Alzheimer’s Disease
  • Migraine
  • Multiple Sclerosis

By Technology
  • Neuroimaging (Computed Tomography, Magnetic Resonance Imaging, Nuclear Medicine Imaging
  • Near-Infrared Spectroscopic Imaging, Electroencephalography, Magnetoencephalographya and Voxel-Based Morphometry)
  • In Vitro Diagnosis
  • Neuroinformatics

By End-user
  • Clinic
  • Hospitals
  • Diagnostic Laboratories

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rise in the Prevalence of Neurological Diseases and Disorders
      • 3.2.2. Technological Advancements in the Field of Medical Science
    • 3.3. Market Challenges
      • 3.3.1. Lack of Skilled Workforce
    • 3.4. Market Trends
      • 3.4.1. Growing Patient Emphasis on Effective and Early Disease Diagnosis
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Neurodiagnostics, by Disease, Technology, End-user and Region (value, volume and price ) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Neurodiagnostics (Value)
      • 5.2.1. Global Neurodiagnostics by: Disease (Value)
        • 5.2.1.1. Alzheimer’s Disease
        • 5.2.1.2. Migraine
        • 5.2.1.3. Multiple Sclerosis
      • 5.2.2. Global Neurodiagnostics by: Technology (Value)
        • 5.2.2.1. Neuroimaging (Computed Tomography, Magnetic Resonance Imaging, Nuclear Medicine Imaging
        • 5.2.2.2. Near-Infrared Spectroscopic Imaging, Electroencephalography, Magnetoencephalographya and Voxel-Based Morphometry)
        • 5.2.2.3. In Vitro Diagnosis
        • 5.2.2.4. Neuroinformatics
      • 5.2.3. Global Neurodiagnostics by: End-user (Value)
        • 5.2.3.1. Clinic
        • 5.2.3.2. Hospitals
        • 5.2.3.3. Diagnostic Laboratories
      • 5.2.4. Global Neurodiagnostics Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Neurodiagnostics (Volume)
      • 5.3.1. Global Neurodiagnostics by: Disease (Volume)
        • 5.3.1.1. Alzheimer’s Disease
        • 5.3.1.2. Migraine
        • 5.3.1.3. Multiple Sclerosis
      • 5.3.2. Global Neurodiagnostics by: Technology (Volume)
        • 5.3.2.1. Neuroimaging (Computed Tomography, Magnetic Resonance Imaging, Nuclear Medicine Imaging
        • 5.3.2.2. Near-Infrared Spectroscopic Imaging, Electroencephalography, Magnetoencephalographya and Voxel-Based Morphometry)
        • 5.3.2.3. In Vitro Diagnosis
        • 5.3.2.4. Neuroinformatics
      • 5.3.3. Global Neurodiagnostics by: End-user (Volume)
        • 5.3.3.1. Clinic
        • 5.3.3.2. Hospitals
        • 5.3.3.3. Diagnostic Laboratories
      • 5.3.4. Global Neurodiagnostics Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Neurodiagnostics (Price)
  • 6. Neurodiagnostics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GE Healthcare (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Siemens Healthineers (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Philips Healthcare (Netherlands)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Hitachi, Ltd. (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Canon, Inc. (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Lifelines Neuro Company, LLC (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Natus Medical Incorporated (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Hoffman-La Roche AG (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. FUJIFILM Holdings Corporation (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Mitsar Co., Ltd. (Russia)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Neurodiagnostics Sale, by Disease, Technology, End-user and Region (value, volume and price ) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Neurodiagnostics (Value)
      • 7.2.1. Global Neurodiagnostics by: Disease (Value)
        • 7.2.1.1. Alzheimer’s Disease
        • 7.2.1.2. Migraine
        • 7.2.1.3. Multiple Sclerosis
      • 7.2.2. Global Neurodiagnostics by: Technology (Value)
        • 7.2.2.1. Neuroimaging (Computed Tomography, Magnetic Resonance Imaging, Nuclear Medicine Imaging
        • 7.2.2.2. Near-Infrared Spectroscopic Imaging, Electroencephalography, Magnetoencephalographya and Voxel-Based Morphometry)
        • 7.2.2.3. In Vitro Diagnosis
        • 7.2.2.4. Neuroinformatics
      • 7.2.3. Global Neurodiagnostics by: End-user (Value)
        • 7.2.3.1. Clinic
        • 7.2.3.2. Hospitals
        • 7.2.3.3. Diagnostic Laboratories
      • 7.2.4. Global Neurodiagnostics Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Neurodiagnostics (Volume)
      • 7.3.1. Global Neurodiagnostics by: Disease (Volume)
        • 7.3.1.1. Alzheimer’s Disease
        • 7.3.1.2. Migraine
        • 7.3.1.3. Multiple Sclerosis
      • 7.3.2. Global Neurodiagnostics by: Technology (Volume)
        • 7.3.2.1. Neuroimaging (Computed Tomography, Magnetic Resonance Imaging, Nuclear Medicine Imaging
        • 7.3.2.2. Near-Infrared Spectroscopic Imaging, Electroencephalography, Magnetoencephalographya and Voxel-Based Morphometry)
        • 7.3.2.3. In Vitro Diagnosis
        • 7.3.2.4. Neuroinformatics
      • 7.3.3. Global Neurodiagnostics by: End-user (Volume)
        • 7.3.3.1. Clinic
        • 7.3.3.2. Hospitals
        • 7.3.3.3. Diagnostic Laboratories
      • 7.3.4. Global Neurodiagnostics Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Neurodiagnostics (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Neurodiagnostics: by Disease(USD Million)
  • Table 2. Neurodiagnostics Alzheimer’s Disease , by Region USD Million (2014-2019)
  • Table 3. Neurodiagnostics Migraine , by Region USD Million (2014-2019)
  • Table 4. Neurodiagnostics Multiple Sclerosis , by Region USD Million (2014-2019)
  • Table 5. Neurodiagnostics: by Technology(USD Million)
  • Table 6. Neurodiagnostics Neuroimaging (Computed Tomography, Magnetic Resonance Imaging, Nuclear Medicine Imaging , by Region USD Million (2014-2019)
  • Table 7. Neurodiagnostics Near-Infrared Spectroscopic Imaging, Electroencephalography, Magnetoencephalographya and Voxel-Based Morphometry) , by Region USD Million (2014-2019)
  • Table 8. Neurodiagnostics In Vitro Diagnosis , by Region USD Million (2014-2019)
  • Table 9. Neurodiagnostics Neuroinformatics , by Region USD Million (2014-2019)
  • Table 10. Neurodiagnostics: by End-user(USD Million)
  • Table 11. Neurodiagnostics Clinic , by Region USD Million (2014-2019)
  • Table 12. Neurodiagnostics Hospitals , by Region USD Million (2014-2019)
  • Table 13. Neurodiagnostics Diagnostic Laboratories , by Region USD Million (2014-2019)
  • Table 14. South America Neurodiagnostics, by Country USD Million (2014-2019)
  • Table 15. South America Neurodiagnostics, by Disease USD Million (2014-2019)
  • Table 16. South America Neurodiagnostics, by Technology USD Million (2014-2019)
  • Table 17. South America Neurodiagnostics, by End-user USD Million (2014-2019)
  • Table 18. Brazil Neurodiagnostics, by Disease USD Million (2014-2019)
  • Table 19. Brazil Neurodiagnostics, by Technology USD Million (2014-2019)
  • Table 20. Brazil Neurodiagnostics, by End-user USD Million (2014-2019)
  • Table 21. Argentina Neurodiagnostics, by Disease USD Million (2014-2019)
  • Table 22. Argentina Neurodiagnostics, by Technology USD Million (2014-2019)
  • Table 23. Argentina Neurodiagnostics, by End-user USD Million (2014-2019)
  • Table 24. Rest of South America Neurodiagnostics, by Disease USD Million (2014-2019)
  • Table 25. Rest of South America Neurodiagnostics, by Technology USD Million (2014-2019)
  • Table 26. Rest of South America Neurodiagnostics, by End-user USD Million (2014-2019)
  • Table 27. Asia Pacific Neurodiagnostics, by Country USD Million (2014-2019)
  • Table 28. Asia Pacific Neurodiagnostics, by Disease USD Million (2014-2019)
  • Table 29. Asia Pacific Neurodiagnostics, by Technology USD Million (2014-2019)
  • Table 30. Asia Pacific Neurodiagnostics, by End-user USD Million (2014-2019)
  • Table 31. China Neurodiagnostics, by Disease USD Million (2014-2019)
  • Table 32. China Neurodiagnostics, by Technology USD Million (2014-2019)
  • Table 33. China Neurodiagnostics, by End-user USD Million (2014-2019)
  • Table 34. Japan Neurodiagnostics, by Disease USD Million (2014-2019)
  • Table 35. Japan Neurodiagnostics, by Technology USD Million (2014-2019)
  • Table 36. Japan Neurodiagnostics, by End-user USD Million (2014-2019)
  • Table 37. India Neurodiagnostics, by Disease USD Million (2014-2019)
  • Table 38. India Neurodiagnostics, by Technology USD Million (2014-2019)
  • Table 39. India Neurodiagnostics, by End-user USD Million (2014-2019)
  • Table 40. South Korea Neurodiagnostics, by Disease USD Million (2014-2019)
  • Table 41. South Korea Neurodiagnostics, by Technology USD Million (2014-2019)
  • Table 42. South Korea Neurodiagnostics, by End-user USD Million (2014-2019)
  • Table 43. Taiwan Neurodiagnostics, by Disease USD Million (2014-2019)
  • Table 44. Taiwan Neurodiagnostics, by Technology USD Million (2014-2019)
  • Table 45. Taiwan Neurodiagnostics, by End-user USD Million (2014-2019)
  • Table 46. Australia Neurodiagnostics, by Disease USD Million (2014-2019)
  • Table 47. Australia Neurodiagnostics, by Technology USD Million (2014-2019)
  • Table 48. Australia Neurodiagnostics, by End-user USD Million (2014-2019)
  • Table 49. Rest of Asia-Pacific Neurodiagnostics, by Disease USD Million (2014-2019)
  • Table 50. Rest of Asia-Pacific Neurodiagnostics, by Technology USD Million (2014-2019)
  • Table 51. Rest of Asia-Pacific Neurodiagnostics, by End-user USD Million (2014-2019)
  • Table 52. Europe Neurodiagnostics, by Country USD Million (2014-2019)
  • Table 53. Europe Neurodiagnostics, by Disease USD Million (2014-2019)
  • Table 54. Europe Neurodiagnostics, by Technology USD Million (2014-2019)
  • Table 55. Europe Neurodiagnostics, by End-user USD Million (2014-2019)
  • Table 56. Germany Neurodiagnostics, by Disease USD Million (2014-2019)
  • Table 57. Germany Neurodiagnostics, by Technology USD Million (2014-2019)
  • Table 58. Germany Neurodiagnostics, by End-user USD Million (2014-2019)
  • Table 59. France Neurodiagnostics, by Disease USD Million (2014-2019)
  • Table 60. France Neurodiagnostics, by Technology USD Million (2014-2019)
  • Table 61. France Neurodiagnostics, by End-user USD Million (2014-2019)
  • Table 62. Italy Neurodiagnostics, by Disease USD Million (2014-2019)
  • Table 63. Italy Neurodiagnostics, by Technology USD Million (2014-2019)
  • Table 64. Italy Neurodiagnostics, by End-user USD Million (2014-2019)
  • Table 65. United Kingdom Neurodiagnostics, by Disease USD Million (2014-2019)
  • Table 66. United Kingdom Neurodiagnostics, by Technology USD Million (2014-2019)
  • Table 67. United Kingdom Neurodiagnostics, by End-user USD Million (2014-2019)
  • Table 68. Netherlands Neurodiagnostics, by Disease USD Million (2014-2019)
  • Table 69. Netherlands Neurodiagnostics, by Technology USD Million (2014-2019)
  • Table 70. Netherlands Neurodiagnostics, by End-user USD Million (2014-2019)
  • Table 71. Rest of Europe Neurodiagnostics, by Disease USD Million (2014-2019)
  • Table 72. Rest of Europe Neurodiagnostics, by Technology USD Million (2014-2019)
  • Table 73. Rest of Europe Neurodiagnostics, by End-user USD Million (2014-2019)
  • Table 74. MEA Neurodiagnostics, by Country USD Million (2014-2019)
  • Table 75. MEA Neurodiagnostics, by Disease USD Million (2014-2019)
  • Table 76. MEA Neurodiagnostics, by Technology USD Million (2014-2019)
  • Table 77. MEA Neurodiagnostics, by End-user USD Million (2014-2019)
  • Table 78. Middle East Neurodiagnostics, by Disease USD Million (2014-2019)
  • Table 79. Middle East Neurodiagnostics, by Technology USD Million (2014-2019)
  • Table 80. Middle East Neurodiagnostics, by End-user USD Million (2014-2019)
  • Table 81. Africa Neurodiagnostics, by Disease USD Million (2014-2019)
  • Table 82. Africa Neurodiagnostics, by Technology USD Million (2014-2019)
  • Table 83. Africa Neurodiagnostics, by End-user USD Million (2014-2019)
  • Table 84. North America Neurodiagnostics, by Country USD Million (2014-2019)
  • Table 85. North America Neurodiagnostics, by Disease USD Million (2014-2019)
  • Table 86. North America Neurodiagnostics, by Technology USD Million (2014-2019)
  • Table 87. North America Neurodiagnostics, by End-user USD Million (2014-2019)
  • Table 88. United States Neurodiagnostics, by Disease USD Million (2014-2019)
  • Table 89. United States Neurodiagnostics, by Technology USD Million (2014-2019)
  • Table 90. United States Neurodiagnostics, by End-user USD Million (2014-2019)
  • Table 91. Canada Neurodiagnostics, by Disease USD Million (2014-2019)
  • Table 92. Canada Neurodiagnostics, by Technology USD Million (2014-2019)
  • Table 93. Canada Neurodiagnostics, by End-user USD Million (2014-2019)
  • Table 94. Mexico Neurodiagnostics, by Disease USD Million (2014-2019)
  • Table 95. Mexico Neurodiagnostics, by Technology USD Million (2014-2019)
  • Table 96. Mexico Neurodiagnostics, by End-user USD Million (2014-2019)
  • Table 97. Neurodiagnostics Sales: by Disease(K Units)
  • Table 98. Neurodiagnostics Sales Alzheimer’s Disease , by Region K Units (2014-2019)
  • Table 99. Neurodiagnostics Sales Migraine , by Region K Units (2014-2019)
  • Table 100. Neurodiagnostics Sales Multiple Sclerosis , by Region K Units (2014-2019)
  • Table 101. Neurodiagnostics Sales: by Technology(K Units)
  • Table 102. Neurodiagnostics Sales Neuroimaging (Computed Tomography, Magnetic Resonance Imaging, Nuclear Medicine Imaging , by Region K Units (2014-2019)
  • Table 103. Neurodiagnostics Sales Near-Infrared Spectroscopic Imaging, Electroencephalography, Magnetoencephalographya and Voxel-Based Morphometry) , by Region K Units (2014-2019)
  • Table 104. Neurodiagnostics Sales In Vitro Diagnosis , by Region K Units (2014-2019)
  • Table 105. Neurodiagnostics Sales Neuroinformatics , by Region K Units (2014-2019)
  • Table 106. Neurodiagnostics Sales: by End-user(K Units)
  • Table 107. Neurodiagnostics Sales Clinic , by Region K Units (2014-2019)
  • Table 108. Neurodiagnostics Sales Hospitals , by Region K Units (2014-2019)
  • Table 109. Neurodiagnostics Sales Diagnostic Laboratories , by Region K Units (2014-2019)
  • Table 110. South America Neurodiagnostics Sales, by Country K Units (2014-2019)
  • Table 111. South America Neurodiagnostics Sales, by Disease K Units (2014-2019)
  • Table 112. South America Neurodiagnostics Sales, by Technology K Units (2014-2019)
  • Table 113. South America Neurodiagnostics Sales, by End-user K Units (2014-2019)
  • Table 114. Brazil Neurodiagnostics Sales, by Disease K Units (2014-2019)
  • Table 115. Brazil Neurodiagnostics Sales, by Technology K Units (2014-2019)
  • Table 116. Brazil Neurodiagnostics Sales, by End-user K Units (2014-2019)
  • Table 117. Argentina Neurodiagnostics Sales, by Disease K Units (2014-2019)
  • Table 118. Argentina Neurodiagnostics Sales, by Technology K Units (2014-2019)
  • Table 119. Argentina Neurodiagnostics Sales, by End-user K Units (2014-2019)
  • Table 120. Rest of South America Neurodiagnostics Sales, by Disease K Units (2014-2019)
  • Table 121. Rest of South America Neurodiagnostics Sales, by Technology K Units (2014-2019)
  • Table 122. Rest of South America Neurodiagnostics Sales, by End-user K Units (2014-2019)
  • Table 123. Asia Pacific Neurodiagnostics Sales, by Country K Units (2014-2019)
  • Table 124. Asia Pacific Neurodiagnostics Sales, by Disease K Units (2014-2019)
  • Table 125. Asia Pacific Neurodiagnostics Sales, by Technology K Units (2014-2019)
  • Table 126. Asia Pacific Neurodiagnostics Sales, by End-user K Units (2014-2019)
  • Table 127. China Neurodiagnostics Sales, by Disease K Units (2014-2019)
  • Table 128. China Neurodiagnostics Sales, by Technology K Units (2014-2019)
  • Table 129. China Neurodiagnostics Sales, by End-user K Units (2014-2019)
  • Table 130. Japan Neurodiagnostics Sales, by Disease K Units (2014-2019)
  • Table 131. Japan Neurodiagnostics Sales, by Technology K Units (2014-2019)
  • Table 132. Japan Neurodiagnostics Sales, by End-user K Units (2014-2019)
  • Table 133. India Neurodiagnostics Sales, by Disease K Units (2014-2019)
  • Table 134. India Neurodiagnostics Sales, by Technology K Units (2014-2019)
  • Table 135. India Neurodiagnostics Sales, by End-user K Units (2014-2019)
  • Table 136. South Korea Neurodiagnostics Sales, by Disease K Units (2014-2019)
  • Table 137. South Korea Neurodiagnostics Sales, by Technology K Units (2014-2019)
  • Table 138. South Korea Neurodiagnostics Sales, by End-user K Units (2014-2019)
  • Table 139. Taiwan Neurodiagnostics Sales, by Disease K Units (2014-2019)
  • Table 140. Taiwan Neurodiagnostics Sales, by Technology K Units (2014-2019)
  • Table 141. Taiwan Neurodiagnostics Sales, by End-user K Units (2014-2019)
  • Table 142. Australia Neurodiagnostics Sales, by Disease K Units (2014-2019)
  • Table 143. Australia Neurodiagnostics Sales, by Technology K Units (2014-2019)
  • Table 144. Australia Neurodiagnostics Sales, by End-user K Units (2014-2019)
  • Table 145. Rest of Asia-Pacific Neurodiagnostics Sales, by Disease K Units (2014-2019)
  • Table 146. Rest of Asia-Pacific Neurodiagnostics Sales, by Technology K Units (2014-2019)
  • Table 147. Rest of Asia-Pacific Neurodiagnostics Sales, by End-user K Units (2014-2019)
  • Table 148. Europe Neurodiagnostics Sales, by Country K Units (2014-2019)
  • Table 149. Europe Neurodiagnostics Sales, by Disease K Units (2014-2019)
  • Table 150. Europe Neurodiagnostics Sales, by Technology K Units (2014-2019)
  • Table 151. Europe Neurodiagnostics Sales, by End-user K Units (2014-2019)
  • Table 152. Germany Neurodiagnostics Sales, by Disease K Units (2014-2019)
  • Table 153. Germany Neurodiagnostics Sales, by Technology K Units (2014-2019)
  • Table 154. Germany Neurodiagnostics Sales, by End-user K Units (2014-2019)
  • Table 155. France Neurodiagnostics Sales, by Disease K Units (2014-2019)
  • Table 156. France Neurodiagnostics Sales, by Technology K Units (2014-2019)
  • Table 157. France Neurodiagnostics Sales, by End-user K Units (2014-2019)
  • Table 158. Italy Neurodiagnostics Sales, by Disease K Units (2014-2019)
  • Table 159. Italy Neurodiagnostics Sales, by Technology K Units (2014-2019)
  • Table 160. Italy Neurodiagnostics Sales, by End-user K Units (2014-2019)
  • Table 161. United Kingdom Neurodiagnostics Sales, by Disease K Units (2014-2019)
  • Table 162. United Kingdom Neurodiagnostics Sales, by Technology K Units (2014-2019)
  • Table 163. United Kingdom Neurodiagnostics Sales, by End-user K Units (2014-2019)
  • Table 164. Netherlands Neurodiagnostics Sales, by Disease K Units (2014-2019)
  • Table 165. Netherlands Neurodiagnostics Sales, by Technology K Units (2014-2019)
  • Table 166. Netherlands Neurodiagnostics Sales, by End-user K Units (2014-2019)
  • Table 167. Rest of Europe Neurodiagnostics Sales, by Disease K Units (2014-2019)
  • Table 168. Rest of Europe Neurodiagnostics Sales, by Technology K Units (2014-2019)
  • Table 169. Rest of Europe Neurodiagnostics Sales, by End-user K Units (2014-2019)
  • Table 170. MEA Neurodiagnostics Sales, by Country K Units (2014-2019)
  • Table 171. MEA Neurodiagnostics Sales, by Disease K Units (2014-2019)
  • Table 172. MEA Neurodiagnostics Sales, by Technology K Units (2014-2019)
  • Table 173. MEA Neurodiagnostics Sales, by End-user K Units (2014-2019)
  • Table 174. Middle East Neurodiagnostics Sales, by Disease K Units (2014-2019)
  • Table 175. Middle East Neurodiagnostics Sales, by Technology K Units (2014-2019)
  • Table 176. Middle East Neurodiagnostics Sales, by End-user K Units (2014-2019)
  • Table 177. Africa Neurodiagnostics Sales, by Disease K Units (2014-2019)
  • Table 178. Africa Neurodiagnostics Sales, by Technology K Units (2014-2019)
  • Table 179. Africa Neurodiagnostics Sales, by End-user K Units (2014-2019)
  • Table 180. North America Neurodiagnostics Sales, by Country K Units (2014-2019)
  • Table 181. North America Neurodiagnostics Sales, by Disease K Units (2014-2019)
  • Table 182. North America Neurodiagnostics Sales, by Technology K Units (2014-2019)
  • Table 183. North America Neurodiagnostics Sales, by End-user K Units (2014-2019)
  • Table 184. United States Neurodiagnostics Sales, by Disease K Units (2014-2019)
  • Table 185. United States Neurodiagnostics Sales, by Technology K Units (2014-2019)
  • Table 186. United States Neurodiagnostics Sales, by End-user K Units (2014-2019)
  • Table 187. Canada Neurodiagnostics Sales, by Disease K Units (2014-2019)
  • Table 188. Canada Neurodiagnostics Sales, by Technology K Units (2014-2019)
  • Table 189. Canada Neurodiagnostics Sales, by End-user K Units (2014-2019)
  • Table 190. Mexico Neurodiagnostics Sales, by Disease K Units (2014-2019)
  • Table 191. Mexico Neurodiagnostics Sales, by Technology K Units (2014-2019)
  • Table 192. Mexico Neurodiagnostics Sales, by End-user K Units (2014-2019)
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Neurodiagnostics: by Disease(USD Million)
  • Table 204. Neurodiagnostics Alzheimer’s Disease , by Region USD Million (2020-2025)
  • Table 205. Neurodiagnostics Migraine , by Region USD Million (2020-2025)
  • Table 206. Neurodiagnostics Multiple Sclerosis , by Region USD Million (2020-2025)
  • Table 207. Neurodiagnostics: by Technology(USD Million)
  • Table 208. Neurodiagnostics Neuroimaging (Computed Tomography, Magnetic Resonance Imaging, Nuclear Medicine Imaging , by Region USD Million (2020-2025)
  • Table 209. Neurodiagnostics Near-Infrared Spectroscopic Imaging, Electroencephalography, Magnetoencephalographya and Voxel-Based Morphometry) , by Region USD Million (2020-2025)
  • Table 210. Neurodiagnostics In Vitro Diagnosis , by Region USD Million (2020-2025)
  • Table 211. Neurodiagnostics Neuroinformatics , by Region USD Million (2020-2025)
  • Table 212. Neurodiagnostics: by End-user(USD Million)
  • Table 213. Neurodiagnostics Clinic , by Region USD Million (2020-2025)
  • Table 214. Neurodiagnostics Hospitals , by Region USD Million (2020-2025)
  • Table 215. Neurodiagnostics Diagnostic Laboratories , by Region USD Million (2020-2025)
  • Table 216. South America Neurodiagnostics, by Country USD Million (2020-2025)
  • Table 217. South America Neurodiagnostics, by Disease USD Million (2020-2025)
  • Table 218. South America Neurodiagnostics, by Technology USD Million (2020-2025)
  • Table 219. South America Neurodiagnostics, by End-user USD Million (2020-2025)
  • Table 220. Brazil Neurodiagnostics, by Disease USD Million (2020-2025)
  • Table 221. Brazil Neurodiagnostics, by Technology USD Million (2020-2025)
  • Table 222. Brazil Neurodiagnostics, by End-user USD Million (2020-2025)
  • Table 223. Argentina Neurodiagnostics, by Disease USD Million (2020-2025)
  • Table 224. Argentina Neurodiagnostics, by Technology USD Million (2020-2025)
  • Table 225. Argentina Neurodiagnostics, by End-user USD Million (2020-2025)
  • Table 226. Rest of South America Neurodiagnostics, by Disease USD Million (2020-2025)
  • Table 227. Rest of South America Neurodiagnostics, by Technology USD Million (2020-2025)
  • Table 228. Rest of South America Neurodiagnostics, by End-user USD Million (2020-2025)
  • Table 229. Asia Pacific Neurodiagnostics, by Country USD Million (2020-2025)
  • Table 230. Asia Pacific Neurodiagnostics, by Disease USD Million (2020-2025)
  • Table 231. Asia Pacific Neurodiagnostics, by Technology USD Million (2020-2025)
  • Table 232. Asia Pacific Neurodiagnostics, by End-user USD Million (2020-2025)
  • Table 233. China Neurodiagnostics, by Disease USD Million (2020-2025)
  • Table 234. China Neurodiagnostics, by Technology USD Million (2020-2025)
  • Table 235. China Neurodiagnostics, by End-user USD Million (2020-2025)
  • Table 236. Japan Neurodiagnostics, by Disease USD Million (2020-2025)
  • Table 237. Japan Neurodiagnostics, by Technology USD Million (2020-2025)
  • Table 238. Japan Neurodiagnostics, by End-user USD Million (2020-2025)
  • Table 239. India Neurodiagnostics, by Disease USD Million (2020-2025)
  • Table 240. India Neurodiagnostics, by Technology USD Million (2020-2025)
  • Table 241. India Neurodiagnostics, by End-user USD Million (2020-2025)
  • Table 242. South Korea Neurodiagnostics, by Disease USD Million (2020-2025)
  • Table 243. South Korea Neurodiagnostics, by Technology USD Million (2020-2025)
  • Table 244. South Korea Neurodiagnostics, by End-user USD Million (2020-2025)
  • Table 245. Taiwan Neurodiagnostics, by Disease USD Million (2020-2025)
  • Table 246. Taiwan Neurodiagnostics, by Technology USD Million (2020-2025)
  • Table 247. Taiwan Neurodiagnostics, by End-user USD Million (2020-2025)
  • Table 248. Australia Neurodiagnostics, by Disease USD Million (2020-2025)
  • Table 249. Australia Neurodiagnostics, by Technology USD Million (2020-2025)
  • Table 250. Australia Neurodiagnostics, by End-user USD Million (2020-2025)
  • Table 251. Rest of Asia-Pacific Neurodiagnostics, by Disease USD Million (2020-2025)
  • Table 252. Rest of Asia-Pacific Neurodiagnostics, by Technology USD Million (2020-2025)
  • Table 253. Rest of Asia-Pacific Neurodiagnostics, by End-user USD Million (2020-2025)
  • Table 254. Europe Neurodiagnostics, by Country USD Million (2020-2025)
  • Table 255. Europe Neurodiagnostics, by Disease USD Million (2020-2025)
  • Table 256. Europe Neurodiagnostics, by Technology USD Million (2020-2025)
  • Table 257. Europe Neurodiagnostics, by End-user USD Million (2020-2025)
  • Table 258. Germany Neurodiagnostics, by Disease USD Million (2020-2025)
  • Table 259. Germany Neurodiagnostics, by Technology USD Million (2020-2025)
  • Table 260. Germany Neurodiagnostics, by End-user USD Million (2020-2025)
  • Table 261. France Neurodiagnostics, by Disease USD Million (2020-2025)
  • Table 262. France Neurodiagnostics, by Technology USD Million (2020-2025)
  • Table 263. France Neurodiagnostics, by End-user USD Million (2020-2025)
  • Table 264. Italy Neurodiagnostics, by Disease USD Million (2020-2025)
  • Table 265. Italy Neurodiagnostics, by Technology USD Million (2020-2025)
  • Table 266. Italy Neurodiagnostics, by End-user USD Million (2020-2025)
  • Table 267. United Kingdom Neurodiagnostics, by Disease USD Million (2020-2025)
  • Table 268. United Kingdom Neurodiagnostics, by Technology USD Million (2020-2025)
  • Table 269. United Kingdom Neurodiagnostics, by End-user USD Million (2020-2025)
  • Table 270. Netherlands Neurodiagnostics, by Disease USD Million (2020-2025)
  • Table 271. Netherlands Neurodiagnostics, by Technology USD Million (2020-2025)
  • Table 272. Netherlands Neurodiagnostics, by End-user USD Million (2020-2025)
  • Table 273. Rest of Europe Neurodiagnostics, by Disease USD Million (2020-2025)
  • Table 274. Rest of Europe Neurodiagnostics, by Technology USD Million (2020-2025)
  • Table 275. Rest of Europe Neurodiagnostics, by End-user USD Million (2020-2025)
  • Table 276. MEA Neurodiagnostics, by Country USD Million (2020-2025)
  • Table 277. MEA Neurodiagnostics, by Disease USD Million (2020-2025)
  • Table 278. MEA Neurodiagnostics, by Technology USD Million (2020-2025)
  • Table 279. MEA Neurodiagnostics, by End-user USD Million (2020-2025)
  • Table 280. Middle East Neurodiagnostics, by Disease USD Million (2020-2025)
  • Table 281. Middle East Neurodiagnostics, by Technology USD Million (2020-2025)
  • Table 282. Middle East Neurodiagnostics, by End-user USD Million (2020-2025)
  • Table 283. Africa Neurodiagnostics, by Disease USD Million (2020-2025)
  • Table 284. Africa Neurodiagnostics, by Technology USD Million (2020-2025)
  • Table 285. Africa Neurodiagnostics, by End-user USD Million (2020-2025)
  • Table 286. North America Neurodiagnostics, by Country USD Million (2020-2025)
  • Table 287. North America Neurodiagnostics, by Disease USD Million (2020-2025)
  • Table 288. North America Neurodiagnostics, by Technology USD Million (2020-2025)
  • Table 289. North America Neurodiagnostics, by End-user USD Million (2020-2025)
  • Table 290. United States Neurodiagnostics, by Disease USD Million (2020-2025)
  • Table 291. United States Neurodiagnostics, by Technology USD Million (2020-2025)
  • Table 292. United States Neurodiagnostics, by End-user USD Million (2020-2025)
  • Table 293. Canada Neurodiagnostics, by Disease USD Million (2020-2025)
  • Table 294. Canada Neurodiagnostics, by Technology USD Million (2020-2025)
  • Table 295. Canada Neurodiagnostics, by End-user USD Million (2020-2025)
  • Table 296. Mexico Neurodiagnostics, by Disease USD Million (2020-2025)
  • Table 297. Mexico Neurodiagnostics, by Technology USD Million (2020-2025)
  • Table 298. Mexico Neurodiagnostics, by End-user USD Million (2020-2025)
  • Table 299. Neurodiagnostics Sales: by Disease(K Units)
  • Table 300. Neurodiagnostics Sales Alzheimer’s Disease , by Region K Units (2020-2025)
  • Table 301. Neurodiagnostics Sales Migraine , by Region K Units (2020-2025)
  • Table 302. Neurodiagnostics Sales Multiple Sclerosis , by Region K Units (2020-2025)
  • Table 303. Neurodiagnostics Sales: by Technology(K Units)
  • Table 304. Neurodiagnostics Sales Neuroimaging (Computed Tomography, Magnetic Resonance Imaging, Nuclear Medicine Imaging , by Region K Units (2020-2025)
  • Table 305. Neurodiagnostics Sales Near-Infrared Spectroscopic Imaging, Electroencephalography, Magnetoencephalographya and Voxel-Based Morphometry) , by Region K Units (2020-2025)
  • Table 306. Neurodiagnostics Sales In Vitro Diagnosis , by Region K Units (2020-2025)
  • Table 307. Neurodiagnostics Sales Neuroinformatics , by Region K Units (2020-2025)
  • Table 308. Neurodiagnostics Sales: by End-user(K Units)
  • Table 309. Neurodiagnostics Sales Clinic , by Region K Units (2020-2025)
  • Table 310. Neurodiagnostics Sales Hospitals , by Region K Units (2020-2025)
  • Table 311. Neurodiagnostics Sales Diagnostic Laboratories , by Region K Units (2020-2025)
  • Table 312. South America Neurodiagnostics Sales, by Country K Units (2020-2025)
  • Table 313. South America Neurodiagnostics Sales, by Disease K Units (2020-2025)
  • Table 314. South America Neurodiagnostics Sales, by Technology K Units (2020-2025)
  • Table 315. South America Neurodiagnostics Sales, by End-user K Units (2020-2025)
  • Table 316. Brazil Neurodiagnostics Sales, by Disease K Units (2020-2025)
  • Table 317. Brazil Neurodiagnostics Sales, by Technology K Units (2020-2025)
  • Table 318. Brazil Neurodiagnostics Sales, by End-user K Units (2020-2025)
  • Table 319. Argentina Neurodiagnostics Sales, by Disease K Units (2020-2025)
  • Table 320. Argentina Neurodiagnostics Sales, by Technology K Units (2020-2025)
  • Table 321. Argentina Neurodiagnostics Sales, by End-user K Units (2020-2025)
  • Table 322. Rest of South America Neurodiagnostics Sales, by Disease K Units (2020-2025)
  • Table 323. Rest of South America Neurodiagnostics Sales, by Technology K Units (2020-2025)
  • Table 324. Rest of South America Neurodiagnostics Sales, by End-user K Units (2020-2025)
  • Table 325. Asia Pacific Neurodiagnostics Sales, by Country K Units (2020-2025)
  • Table 326. Asia Pacific Neurodiagnostics Sales, by Disease K Units (2020-2025)
  • Table 327. Asia Pacific Neurodiagnostics Sales, by Technology K Units (2020-2025)
  • Table 328. Asia Pacific Neurodiagnostics Sales, by End-user K Units (2020-2025)
  • Table 329. China Neurodiagnostics Sales, by Disease K Units (2020-2025)
  • Table 330. China Neurodiagnostics Sales, by Technology K Units (2020-2025)
  • Table 331. China Neurodiagnostics Sales, by End-user K Units (2020-2025)
  • Table 332. Japan Neurodiagnostics Sales, by Disease K Units (2020-2025)
  • Table 333. Japan Neurodiagnostics Sales, by Technology K Units (2020-2025)
  • Table 334. Japan Neurodiagnostics Sales, by End-user K Units (2020-2025)
  • Table 335. India Neurodiagnostics Sales, by Disease K Units (2020-2025)
  • Table 336. India Neurodiagnostics Sales, by Technology K Units (2020-2025)
  • Table 337. India Neurodiagnostics Sales, by End-user K Units (2020-2025)
  • Table 338. South Korea Neurodiagnostics Sales, by Disease K Units (2020-2025)
  • Table 339. South Korea Neurodiagnostics Sales, by Technology K Units (2020-2025)
  • Table 340. South Korea Neurodiagnostics Sales, by End-user K Units (2020-2025)
  • Table 341. Taiwan Neurodiagnostics Sales, by Disease K Units (2020-2025)
  • Table 342. Taiwan Neurodiagnostics Sales, by Technology K Units (2020-2025)
  • Table 343. Taiwan Neurodiagnostics Sales, by End-user K Units (2020-2025)
  • Table 344. Australia Neurodiagnostics Sales, by Disease K Units (2020-2025)
  • Table 345. Australia Neurodiagnostics Sales, by Technology K Units (2020-2025)
  • Table 346. Australia Neurodiagnostics Sales, by End-user K Units (2020-2025)
  • Table 347. Rest of Asia-Pacific Neurodiagnostics Sales, by Disease K Units (2020-2025)
  • Table 348. Rest of Asia-Pacific Neurodiagnostics Sales, by Technology K Units (2020-2025)
  • Table 349. Rest of Asia-Pacific Neurodiagnostics Sales, by End-user K Units (2020-2025)
  • Table 350. Europe Neurodiagnostics Sales, by Country K Units (2020-2025)
  • Table 351. Europe Neurodiagnostics Sales, by Disease K Units (2020-2025)
  • Table 352. Europe Neurodiagnostics Sales, by Technology K Units (2020-2025)
  • Table 353. Europe Neurodiagnostics Sales, by End-user K Units (2020-2025)
  • Table 354. Germany Neurodiagnostics Sales, by Disease K Units (2020-2025)
  • Table 355. Germany Neurodiagnostics Sales, by Technology K Units (2020-2025)
  • Table 356. Germany Neurodiagnostics Sales, by End-user K Units (2020-2025)
  • Table 357. France Neurodiagnostics Sales, by Disease K Units (2020-2025)
  • Table 358. France Neurodiagnostics Sales, by Technology K Units (2020-2025)
  • Table 359. France Neurodiagnostics Sales, by End-user K Units (2020-2025)
  • Table 360. Italy Neurodiagnostics Sales, by Disease K Units (2020-2025)
  • Table 361. Italy Neurodiagnostics Sales, by Technology K Units (2020-2025)
  • Table 362. Italy Neurodiagnostics Sales, by End-user K Units (2020-2025)
  • Table 363. United Kingdom Neurodiagnostics Sales, by Disease K Units (2020-2025)
  • Table 364. United Kingdom Neurodiagnostics Sales, by Technology K Units (2020-2025)
  • Table 365. United Kingdom Neurodiagnostics Sales, by End-user K Units (2020-2025)
  • Table 366. Netherlands Neurodiagnostics Sales, by Disease K Units (2020-2025)
  • Table 367. Netherlands Neurodiagnostics Sales, by Technology K Units (2020-2025)
  • Table 368. Netherlands Neurodiagnostics Sales, by End-user K Units (2020-2025)
  • Table 369. Rest of Europe Neurodiagnostics Sales, by Disease K Units (2020-2025)
  • Table 370. Rest of Europe Neurodiagnostics Sales, by Technology K Units (2020-2025)
  • Table 371. Rest of Europe Neurodiagnostics Sales, by End-user K Units (2020-2025)
  • Table 372. MEA Neurodiagnostics Sales, by Country K Units (2020-2025)
  • Table 373. MEA Neurodiagnostics Sales, by Disease K Units (2020-2025)
  • Table 374. MEA Neurodiagnostics Sales, by Technology K Units (2020-2025)
  • Table 375. MEA Neurodiagnostics Sales, by End-user K Units (2020-2025)
  • Table 376. Middle East Neurodiagnostics Sales, by Disease K Units (2020-2025)
  • Table 377. Middle East Neurodiagnostics Sales, by Technology K Units (2020-2025)
  • Table 378. Middle East Neurodiagnostics Sales, by End-user K Units (2020-2025)
  • Table 379. Africa Neurodiagnostics Sales, by Disease K Units (2020-2025)
  • Table 380. Africa Neurodiagnostics Sales, by Technology K Units (2020-2025)
  • Table 381. Africa Neurodiagnostics Sales, by End-user K Units (2020-2025)
  • Table 382. North America Neurodiagnostics Sales, by Country K Units (2020-2025)
  • Table 383. North America Neurodiagnostics Sales, by Disease K Units (2020-2025)
  • Table 384. North America Neurodiagnostics Sales, by Technology K Units (2020-2025)
  • Table 385. North America Neurodiagnostics Sales, by End-user K Units (2020-2025)
  • Table 386. United States Neurodiagnostics Sales, by Disease K Units (2020-2025)
  • Table 387. United States Neurodiagnostics Sales, by Technology K Units (2020-2025)
  • Table 388. United States Neurodiagnostics Sales, by End-user K Units (2020-2025)
  • Table 389. Canada Neurodiagnostics Sales, by Disease K Units (2020-2025)
  • Table 390. Canada Neurodiagnostics Sales, by Technology K Units (2020-2025)
  • Table 391. Canada Neurodiagnostics Sales, by End-user K Units (2020-2025)
  • Table 392. Mexico Neurodiagnostics Sales, by Disease K Units (2020-2025)
  • Table 393. Mexico Neurodiagnostics Sales, by Technology K Units (2020-2025)
  • Table 394. Mexico Neurodiagnostics Sales, by End-user K Units (2020-2025)
  • Table 395. Research Programs/Design for This Report
  • Table 396. Key Data Information from Secondary Sources
  • Table 397. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Neurodiagnostics: by Disease USD Million (2014-2019)
  • Figure 5. Global Neurodiagnostics: by Technology USD Million (2014-2019)
  • Figure 6. Global Neurodiagnostics: by End-user USD Million (2014-2019)
  • Figure 7. South America Neurodiagnostics Share (%), by Country
  • Figure 8. Asia Pacific Neurodiagnostics Share (%), by Country
  • Figure 9. Europe Neurodiagnostics Share (%), by Country
  • Figure 10. MEA Neurodiagnostics Share (%), by Country
  • Figure 11. North America Neurodiagnostics Share (%), by Country
  • Figure 12. Global Neurodiagnostics: by Disease K Units (2014-2019)
  • Figure 13. Global Neurodiagnostics: by Technology K Units (2014-2019)
  • Figure 14. Global Neurodiagnostics: by End-user K Units (2014-2019)
  • Figure 15. South America Neurodiagnostics Share (%), by Country
  • Figure 16. Asia Pacific Neurodiagnostics Share (%), by Country
  • Figure 17. Europe Neurodiagnostics Share (%), by Country
  • Figure 18. MEA Neurodiagnostics Share (%), by Country
  • Figure 19. North America Neurodiagnostics Share (%), by Country
  • Figure 20. Global Neurodiagnostics share by Players 2019 (%)
  • Figure 21. Global Neurodiagnostics share by Players (Top 3) 2019(%)
  • Figure 22. Global Neurodiagnostics share by Players (Top 5) 2019(%)
  • Figure 23. BCG Matrix for key Companies
  • Figure 24. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 25. GE Healthcare (United States) Revenue: by Geography 2019
  • Figure 26. Siemens Healthineers (Germany) Revenue, Net Income and Gross profit
  • Figure 27. Siemens Healthineers (Germany) Revenue: by Geography 2019
  • Figure 28. Philips Healthcare (Netherlands) Revenue, Net Income and Gross profit
  • Figure 29. Philips Healthcare (Netherlands) Revenue: by Geography 2019
  • Figure 30. Hitachi, Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 31. Hitachi, Ltd. (Japan) Revenue: by Geography 2019
  • Figure 32. Canon, Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 33. Canon, Inc. (Japan) Revenue: by Geography 2019
  • Figure 34. Lifelines Neuro Company, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 35. Lifelines Neuro Company, LLC (United States) Revenue: by Geography 2019
  • Figure 36. Natus Medical Incorporated (United States) Revenue, Net Income and Gross profit
  • Figure 37. Natus Medical Incorporated (United States) Revenue: by Geography 2019
  • Figure 38. Hoffman-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 39. Hoffman-La Roche AG (Switzerland) Revenue: by Geography 2019
  • Figure 40. FUJIFILM Holdings Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 41. FUJIFILM Holdings Corporation (Japan) Revenue: by Geography 2019
  • Figure 42. Mitsar Co., Ltd. (Russia) Revenue, Net Income and Gross profit
  • Figure 43. Mitsar Co., Ltd. (Russia) Revenue: by Geography 2019
  • Figure 44. Global Neurodiagnostics: by Disease USD Million (2020-2025)
  • Figure 45. Global Neurodiagnostics: by Technology USD Million (2020-2025)
  • Figure 46. Global Neurodiagnostics: by End-user USD Million (2020-2025)
  • Figure 47. South America Neurodiagnostics Share (%), by Country
  • Figure 48. Asia Pacific Neurodiagnostics Share (%), by Country
  • Figure 49. Europe Neurodiagnostics Share (%), by Country
  • Figure 50. MEA Neurodiagnostics Share (%), by Country
  • Figure 51. North America Neurodiagnostics Share (%), by Country
  • Figure 52. Global Neurodiagnostics: by Disease K Units (2020-2025)
  • Figure 53. Global Neurodiagnostics: by Technology K Units (2020-2025)
  • Figure 54. Global Neurodiagnostics: by End-user K Units (2020-2025)
  • Figure 55. South America Neurodiagnostics Share (%), by Country
  • Figure 56. Asia Pacific Neurodiagnostics Share (%), by Country
  • Figure 57. Europe Neurodiagnostics Share (%), by Country
  • Figure 58. MEA Neurodiagnostics Share (%), by Country
  • Figure 59. North America Neurodiagnostics Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • GE Healthcare (United States)
  • Siemens Healthineers (Germany)
  • Philips Healthcare (Netherlands)
  • Hitachi, Ltd. (Japan)
  • Canon, Inc. (Japan)
  • Lifelines Neuro Company, LLC (United States)
  • Natus Medical Incorporated (United States)
  • Hoffman-La Roche AG (Switzerland)
  • FUJIFILM Holdings Corporation (Japan)
  • Mitsar Co., Ltd. (Russia)
Additional players considered in the study are as follows:
Advanced Brain Monitoring (United States) , Thermo Fisher Scientific, Inc. (United States) , Bio-Rad Laboratories (United States) , QIAGEN N.V. (Netherlands)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation